| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EMP1 |
| Uniprot No | P54849 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-157aa |
| 氨基酸序列 | MLVLLAGIFVVHIATVIMLFVSTIANVWLVSNTVDASVGLWKNCTNISCSDSLSYASEDALKTVQAFMILSIIFCVIALLVFVFQLFTMEKGNRFFLSGATTLVCWLCILVGVSIYTSHYANRDGTQYHHGYSYILGWICFCFSFIIGVLYLVLRKK |
| 分子量 | 43.01 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人EMP1蛋白的几篇代表性文献示例(内容为生成示例，仅供学术参考，需通过数据库验证真实性)：
---
1. **文献名称**：*Recombinant human EMP1 protein induces apoptosis in gastric cancer cells via MAPK signaling pathway*
**作者**：Li, X., Wang, Y., Chen, J.
**摘要**：本研究通过大肠杆菌表达系统成功制备了重组人EMP1蛋白，并发现其可通过激活MAPK通路诱导胃癌细胞凋亡，为EMP1在肿瘤治疗中的潜在应用提供依据。
2. **文献名称**：*Expression and purification of functionally active EMP1 in mammalian cells and its role in cell migration*
**作者**：Smith, R., Taylor, K., Guo, H.
**摘要**：作者利用哺乳动物细胞系统表达重组EMP1.证实其可调控上皮细胞迁移，并通过蛋白质互作分析揭示其与整合素β1的相互作用机制。
3. **文献名称**：*Structural characterization of EMP1 and its implications in neural development*
**作者**：Zhang, L., Liu, W., Zhou, M.
**摘要**：通过X射线晶体学解析重组EMP1的蛋白结构，发现其胞外域与髓鞘形成相关，提示EMP1可能参与神经退行性疾病的病理过程。
4. **文献名称**：*EMP1 as a biomarker in breast cancer: Roles in EMT and therapeutic resistance*
**作者**：Martinez, E., Kim, S., Patel, R.
**摘要**：研究证实，重组EMP1蛋白可促进乳腺癌细胞上皮-间质转化(EMT)，并与化疗耐药性相关，提示其可作为预后标志物或治疗靶点。
---
**提示**：以上示例为生成内容，实际文献需通过PubMed、Web of Science等平台检索关键词如“recombinant EMP1 protein”“EMP1 function”验证。真实研究多聚焦于EMP1在肿瘤、神经发育及细胞黏附中的作用。
Recombinant human EMP1 (Epithelial Membrane Protein 1), also known as CLDN1 or TMP, is a transmembrane glycoprotein belonging to the peripheral myelin protein 22 (PMP22) family. It plays a regulatory role in cell adhesion, proliferation, and differentiation by participating in intracellular signaling pathways and modulating membrane dynamics. Structurally, EMP1 contains four transmembrane domains, intracellular N- and C-termini, and conserved glycosylation sites critical for its biological functions.
This protein is ubiquitously expressed in epithelial and endothelial tissues and has been implicated in organ development, tissue homeostasis, and pathological conditions. Research highlights its dual roles in cancer progression—acting as either a tumor suppressor or promoter depending on context—through interactions with extracellular matrix components and growth factor receptors like EGFR. Dysregulation of EMP1 is associated with carcinomas, inflammatory diseases, and metabolic disorders.
Recombinant EMP1 is typically produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications. Its applications span structural studies, drug discovery, and functional assays investigating epithelial-mesenchymal transition or cell-cell communication. Recent studies explore its potential as a diagnostic biomarker or therapeutic target, particularly in cancers and wound-healing processes. Characterization methods include SDS-PAGE, Western blotting, and mass spectrometry to verify molecular weight (~22 kDa) and glycosylation patterns.
×
